Financials data is unavailable for this security.
View more
Year on year Aspen Pharmacare Holdings Ltd had net income fall -15.76% from 5.23bn to 4.40bn despite a 9.82% increase in revenues from 40.71bn to 44.71bn. An increase in the cost of goods sold as a percentage of sales from 53.49% to 56.48% was a component in the falling net income despite rising revenues.
| Gross margin | 43.52% |
|---|---|
| Net profit margin | 9.85% |
| Operating margin | 15.65% |
| Return on assets | 3.22% |
|---|---|
| Return on equity | 5.15% |
| Return on investment | 3.90% |
More ▼
Cash flow in ZARView more
In 2024, Aspen Pharmacare Holdings Ltd did not generate a significant amount of cash. However, the company earned 6.23bn from its operations for a Cash Flow Margin of 13.92%. In addition the company generated 3.62bn cash from financing while 9.47bn was spent on investing.
| Cash flow per share | 12.10 |
|---|---|
| Price/Cash flow per share | 16.15 |
| Book value per share | 191.03 |
|---|---|
| Tangible book value per share | 29.37 |
More ▼
Balance sheet in ZARView more
| Current ratio | 1.81 |
|---|---|
| Quick ratio | 1.07 |
| Total debt/total equity | 0.4296 |
|---|---|
| Total debt/total capital | 0.3005 |
More ▼
Growth rates in ZAR
Year on year, growth in dividends per share increased 4.97% while earnings per share excluding extraordinary items fell by -15.76%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized earnings per share growth ranks highest in its industry.
| Div yield(5 year avg) | 1.47% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 36.21% |
| EPS growth(5 years) | 21.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -15.76 |
More ▼
